Akero Therapeutics, Inc.

NasdaqGS:AKRO Stock Report

Market Cap: US$2.0b

Akero Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:AKRO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 Dec 24SellUS$86,735William WhiteIndividual2,817US$30.79
10 Dec 24SellUS$72,911Timothy RolphIndividual2,368US$30.79
10 Dec 24SellUS$241,855Andrew ChengIndividual7,855US$30.79
10 Dec 24SellUS$77,067Jonathan YoungIndividual2,503US$30.79
10 Dec 24SellUS$86,520Catriona YaleIndividual2,810US$30.79
10 Dec 24SellUS$28,481Patrick LamyIndividual925US$30.79
10 Sep 24SellUS$45,501Andrew ChengIndividual1,738US$26.18
10 Sep 24SellUS$14,059Timothy RolphIndividual537US$26.18
10 Sep 24SellUS$16,729William WhiteIndividual639US$26.18
10 Sep 24SellUS$16,677Catriona YaleIndividual637US$26.18
10 Sep 24SellUS$14,870Jonathan YoungIndividual568US$26.18
11 Jun 24SellUS$178,728Andrew ChengIndividual7,894US$22.64
11 Jun 24SellUS$53,886Timothy RolphIndividual2,380US$22.64
11 Jun 24SellUS$12,883Patrick LamyIndividual569US$22.64
11 Jun 24SellUS$64,094William WhiteIndividual2,831US$22.64
11 Jun 24SellUS$63,961Catriona YaleIndividual2,825US$22.64
11 Jun 24SellUS$56,965Jonathan YoungIndividual2,516US$22.64
13 Mar 24SellUS$18,443Jonathan YoungIndividual651US$28.33
13 Mar 24SellUS$20,483Catriona YaleIndividual723US$28.33
13 Mar 24SellUS$20,511William WhiteIndividual724US$28.33
13 Mar 24SellUS$55,782Andrew ChengIndividual1,969US$28.33
13 Mar 24SellUS$17,536Timothy RolphIndividual619US$28.33

Insider Trading Volume

Insider Buying: AKRO insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of AKRO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,207,9821.56%
Public Companies2,525,2523.27%
VC/PE Firms5,233,9896.77%
Hedge Funds5,919,4357.66%
Institutions62,397,01180.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.3%.

Top Shareholders

Top 25 shareholders own 93.59% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.3%
Wellington Management Group LLP
7,896,632US$225.5m54.4%0.04%
10.1%
Janus Henderson Group plc
7,077,478US$202.1m2.93%0.08%
8.48%
RTW Investments, LP
5,919,435US$169.1m8.97%2.51%
8.23%
BlackRock, Inc.
5,747,790US$164.2m2.88%no data
7.5%
General Atlantic Service Company, L.P.
5,233,989US$149.5m0%2.92%
7.32%
T. Rowe Price Group, Inc.
5,108,455US$145.9m-13.6%0.01%
5.27%
The Vanguard Group, Inc.
3,676,581US$105.0m-0.77%no data
4%
Alkeon Capital Management, LLC
2,791,437US$79.7m-0.08%0.56%
3.62%
Pfizer Inc.
2,525,252US$72.1m0%no data
3.59%
State Street Global Advisors, Inc.
2,502,946US$71.5m-6.93%no data
2.89%
AllianceBernstein L.P.
2,017,088US$57.6m5.73%0.02%
2.46%
Perceptive Advisors LLC
1,714,806US$49.0m14.3%1.18%
2.4%
Tavistock Life Sciences
1,676,733US$47.9m0%3.42%
2.25%
Geode Capital Management, LLC
1,571,012US$44.9m-2.97%no data
1.99%
Redmile Group, LLC
1,387,479US$39.6m-14.1%2.25%
1.88%
Point72 Asset Management, L.P.
1,313,361US$37.5m0%0.1%
1.57%
Baker Bros. Advisors LP
1,097,082US$31.3m0%0.32%
1.35%
Emerald Advisers, LLC
939,628US$26.8m-0.06%0.59%
1.34%
Rock Springs Capital Management LP
933,399US$26.7m-13.1%0.94%
1.15%
Logos Global Management, L.P.
800,000US$22.8m0%2.9%
1.09%
Yiheng Capital Management, L.P.
758,769US$21.7m-47.1%4.1%
1.03%
Long Focus Capital Management LLC
719,604US$20.6m0%1.89%
0.99%
Deep Track Capital, LP
689,784US$19.7m0%0.64%
0.92%
Silverarc Capital Management, LLC
639,840US$18.3m2.36%4.4%
0.84%
Northern Trust Global Investments
584,584US$16.7m-0.56%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:15
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Akero Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Alexandria HammondBofA Global Research
Edward NashCanaccord Genuity